Skip to main content

Novel tumor-selective lethal miRNAs for the treatment of head and neck cancer

Objective

MiRacle focuses on the development of a therapeutic formulation for the treatment of head and neck cancer. Head and neck cancer contributes to approximately 5% of all cancers in the Western world. Unfortunately the majority of H&N cancer patients present with advanced stages of disease. These patients frequently develop locoregional recurrences, distant metastasis and/or second primary tumors resulting in 5-years survival rates of less than 60% The development of novel anti-cancer agents to improve outcome is therefore urgently awaited. The goal of MiRacle is the advancement of a therapeutic tumor-killing miRNA formulation towards the clinic by combining two innovative technologies, i.e. therapeutic miRNA and head and neck tumor specific targeted drug delivery. Such a project requires (1) expertise in the therapeutic application of miRNA (InteRNA) and knowledge on the synthesis of biochemical active miRNA (Biospring), (2) knowledge of drug formulations to deliver the therapeutic miRNA into humans (IC) and understanding the synthesis of complex drug formulations (Polymun), plus (3) in-depth knowledge of the therapeutic indication, e.g. H&N cancer (VUmc) and skilfulness in toxicity tests that are required for RNA based drug registration (LPT). We believe that this project encompasses all parties that are required to successfully bring a tumor killing miRNA towards registration for first in human testing.

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/head and neck cancer

Call for proposal

FP7-SME-2013
See other projects for this call

Funding Scheme

BSG-SME - Research for SMEs

Coordinator

STICHTING VUMC
Address
De Boelelaan 1117
1081 HV Amsterdam
Netherlands
Activity type
Research Organisations
EU contribution
€ 3 961,73
Administrative Contact
Yvonne Koppelman (Mrs.)

Participants (8)

QUIET THERAPEUTICS LTD

Participation ended

Israel
EU contribution
€ 268 142,60
Address
Yakhin Industrial Park
78172 Ashkelon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ron Lahav (Dr.)
BIOSPRING GESELLSCHAFT FUR BIOTECHNOLOGIE MBH
Germany
EU contribution
€ 182 241,75
Address
Alt-fechenheim 34
60386 Frankfurt Am Main
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jorg Hauf (Dr.)
INTERNA TECHNOLOGIES BV
Netherlands
EU contribution
€ 542 678,25
Address
Jonkerbosplein 52
6534 AB Nijmegen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jack Veuskens (Dr.)
LPT LABORATORY OF PHARMACOLOGY AND TOXICOLOGY GMBH & CO KG
Germany
EU contribution
€ 7 500
Address
Redderweg 8
21147 Hamburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jost Leuschner (Dr.)
OCTOPLUS NV

Participation ended

Netherlands
EU contribution
€ 9 248
Address
Zernikedreef 12
2333 CL Leiden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Anton Mat
INNOVACENTRIC
Belgium
EU contribution
€ 152 689,40
Address
Elf Novemberlaan 16
3500 Hasselt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jack Veuskens (Dr.)
POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH
Austria
EU contribution
€ 2 000
Address
Donaustrasse 99
3400 Klosterneuburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Dietmar Kantiger
STICHTING VU
Netherlands
EU contribution
€ 3 538,27
Address
De Boelelaan 1105
1081 HV Amsterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Michel Telkamp (Mr.)